Company profile: Spectral Medical
1.1 - Company Overview
Company description
- Provider of therapies and diagnostics for septic shock and sepsis risk, including Toraymyxin (PMX) hemoperfusion to remove endotoxin and the Endotoxin Activity Assay (EAA). Conducts the Tigris Phase 3 study of PMX with standard care. Also offers the DIMI hemodialysis system for continuous renal replacement therapy, licensed for hospitals, clinics, and homes in Canada and the USA, and the SAMI device for continuous renal replacement therapy.
Products and services
- Toraymyxin (PMX): A clinical-grade therapeutic hemoperfusion device that removes endotoxin from the bloodstream, used in the treatment of septic shock
- Tigris Clinical Trial: A Phase 3 confirmatory study evaluating PMX in addition to standard care for treating endotoxemia and septic shock
- Endotoxin Activity Assay (EAA): A diagnostic-grade blood assay that measures endotoxin levels to assess the risk of developing sepsis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spectral Medical
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
NovaDigm Therapeutics
HQ: United States
Website
- Description: Provider of vaccines that protect patients from contracting fungal and bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaDigm Therapeutics company profile →
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
Agenovir
HQ: United States
Website
- Description: Provider of novel antiviral therapeutics for diseases associated with viral reservoirs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agenovir company profile →
Armata Pharmaceuticals
HQ: United States
Website
- Description: Provider of bacteriophage-based therapeutics, including AP-PA02 for Pseudomonas aeruginosa respiratory infections, AP-SA02 for drug-resistant Staphylococcus aureus (MRSA/VRSA), and AP-PA03 for P. aeruginosa pneumonia, plus a proprietary synthetic phage engineering platform, phage discovery and phenotyping, and bioinformatics-enabled phage analyses to enhance efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armata Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spectral Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spectral Medical
2.2 - Growth funds investing in similar companies to Spectral Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spectral Medical
4.2 - Public trading comparable groups for Spectral Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →